Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration to Optimize the Hadoop Stack and Advance Big Data Technologies in Genomics

By LabMedica International staff writers
Posted on 07 Aug 2012
NextBio (Santa Clara, CA, USA) and Intel (Santa Clara, CA, USA) announced a partnership geared at optimizing and stabilizing the Hadoop stack and advancing the use of “Big Data” technologies in genomics. More...


As a part of this collaboration, the NextBio and Intel engineers will apply experience they have gained from NextBio’s use of Big Data technologies to the improvement of HDFS (Hadoop distributed file system), Hadoop, and HBase. Any enhancements that NextBio engineers make to the Hadoop stack will be contributed to the open-source community. Intel will also showcase NextBio’s use of Big Data. Hadoop is a distributed work manager for huge amounts of data on a large number of systems. The system is also involved in monitoring, failover, and scheduling.

“NextBio is positioned at the intersection of genomics and Big Data. Every day we deal with the three Vs [volume, variety, and velocity] associated with big Data--we, our collaborators, and our users are adding large volumes of a variety of molecular data to NextBio at an increasing velocity,” said Dr. Satnam Alag, chief technology officer and vice president of engineering at NextBio. “Without the implementation of our algorithms in the MapReduce framework, operational expertise in HDFS, Hadoop, and HBase, and investments in building our secure cloud-based infrastructure, it would have been impossible for us to scale cost-effectively to handle this large-scale data.”

Hadoop is designed as a distributed work manager for huge amounts of data on a large number of systems. However, Hadoop is more than that in that it is also about monitoring, failover, and scheduling. “Intel is firmly committed to the wide adoption and use of big data technologies such as HDFS, Hadoop, and HBase across all industries that need to analyze large amounts of data,” said Girish Juneja, CTO and general manager, Big Data software and services, Intel. “Complex data requiring compute-intensive analysis needs not only big data open source, but a combination of hardware and software management optimizations to help deliver needed scale with a high return on investment. Intel is working closely with NextBio to deliver this showcase reference to the Big Data community and life science industry.”

“The use of big data technologies at NextBio enables researchers and clinicians to mine billions of data points in real-time to discover new biomarkers, clinically assess targets and drug profiles, optimally design clinical trials, and interpret patient molecular data,” Dr. Alag continued. “NextBio has invested significantly in the use of Big Data technologies to handle the tsunami of genomic data being generated and its expected exponential growth. As we further scale our infrastructure to handle this growing data resource, we are excited to work with Intel to make the Hadoop stack better and give back to the open-source community.”

NextBio provides a cutting-edge scientific platform to aggregate and interpret large quantities of genomic and other life sciences data for research and clinical applications. NextBio’s platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which precomputes billions of vital connections between disparate public and proprietary sources of clinical and experimental data. In doing so, the platform enables interoperability from instrument readouts to data interpretation for translational research and discovery.

Backed by highly scalable, big data technology capable of analyzing petabytes of data in real-time, NextBio’s platform is delivered as a SaaS (software as a service) solution resulting in quick deployment and rapid return on investment.

Related Links:

NextBio
Intel



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.